Skip to main content Skip to section navigation Skip to footer
Lexaria Bioscience Corp.Lexaria BioscienceLexaria Bioscience
Lexaria Bioscience Corp.

NASDAQ:LEXX; NASDAQ WARRANT:LEXXW

  • Home
  • About
    • Management
    • Board of Directors
    • Advisors & Consultants
  • Technology
    • Overview
    • Commercial Applications
    • Research
    • Patent Portfolio
  • Licensing Opportunities
  • Investors
Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Presentations
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • 2022 Annual General Meeting
    • FAQ
  • Analyst Coverage
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Legend Removal
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Aug 31, 2017 7:55am EDT

University of British Columbia to Perform Clinical Study on the Cardiovascular and Cognitive Health Effects of Lexaria's TurboCBD(TM)

Aug 10, 2017 9:00am EDT

CEO Chris Bunka was Interviewed on Uptick Network Discussing Company’s Positive Future Progress

Jul 20, 2017 8:00am EDT

National Research Council and Lexaria Bioscience Commence Laboratory Work

Jul 18, 2017 8:00am EDT

Lexaria Bioscience Awarded Australian Patent For Cannabinoid Infused Edibles

Jun 22, 2017 8:00am EDT

Lexaria Files New Patent Application

May 30, 2017 7:50am EDT

Lexaria's Ambarii Corporation Announces LOI With Naturally Splendid to Distribute CBD Melts in Japan and South Korea

May 19, 2017 8:00am EDT

Lexaria raises US$1M from Warrant Exercise

May 10, 2017 8:00am EDT

Lexaria Announces Research on Nonsteroidal Anti-Inflammatory Drugs

May 04, 2017 8:00am EDT

Lexaria Announces R&D on Nicotine

May 02, 2017 8:05am EDT

Lexaria Announces Million Dollar Research and Development Program

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Lexaria Bioscience Corp. (NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

250.765.6424
info@lexariabioscience.com

Lexaria Bioscience Corp.
#100-740 McCurdy Road
Kelowna, BC, V1X2P7

Privacy Policy

General Disclaimer:
No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases…

Read More

Copyright ©2022 All rights reserved.

Back to the top